Log In
BCIQ
Print this Print this
 

Rova-T, rovalpituzumab tesirine (SC16LD6.5)

  Manage Alerts
Collapse Summary General Information
Company AbbVie Inc.
DescriptionAntibody-drug conjugate (ADC) composed of a humanized mAb against delta-like 3 (DLL3) and a pyrrolobenzodiazepine (PBD) dimer toxin
Molecular Target Delta-like 3 (DLL3)
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$9,800.0M

$2,000.0M

$4,000.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/25/2016

Undisclosed

Undisclosed

Undisclosed

06/01/2016

$9,800.0M

$2,000.0M

$4,000.0M

Get a free BioCentury trial today